WANTAI BIOLOGICAL(603392)

Search documents
万泰生物(603392) - 万泰生物投资者关系活动记录表(2023年10月)
2023-10-31 10:31
Group 1: Company Overview and Financial Performance - The company, Wantai Biological Pharmacy Enterprise Co., Ltd., held an earnings conference call on October 30, 2023, to discuss its Q3 2023 performance and future development plans [2]. - The company reported significant investments in R&D to enhance its product pipeline, focusing on vaccines and diagnostic reagents [3]. Group 2: Product Pipeline and Development - The product pipeline includes various vaccines such as hepatitis E vaccine, bivalent HPV vaccine, and 9-valent HPV vaccine, showcasing a rich and competitive market potential [3]. - The company is actively advancing the clinical trials for its vaccines, including the VZV-7D vaccine, which has completed Phase II trials and is preparing for Phase III [4]. Group 3: Market Expansion and Collaborations - Wantai Biological is the only company globally to have a formally approved hepatitis E vaccine, with ongoing efforts to expand its market presence and accessibility [5]. - The company has submitted registration documents for its bivalent HPV vaccine in several countries, including Morocco and Thailand, and has begun sales in Thailand and Nepal [5]. Group 4: Financial Management and Risk Control - The company maintains a controlled risk status regarding accounts receivable, with no significant impairment signs, and emphasizes timely collection efforts [6]. - In light of the current low stock prices, the management is focused on enhancing long-term value and is open to share buybacks based on market conditions [6]. Group 5: Strategic Outlook - The company is committed to building partnerships in countries along the "Belt and Road" initiative to promote its products globally [7]. - The IVD business faces increasing competition post-collective procurement, but the company leverages its long-term R&D collaborations to maintain a competitive edge [7].
万泰生物(603392) - 2023 Q3 - 季度财报
2023-10-27 16:00
Financial Performance - The company's operating revenue for Q3 2023 was ¥805,253,559.20, a decrease of 70.40% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥106,006,064.52, down 91.53% year-on-year[3]. - The basic earnings per share for Q3 2023 was ¥0.08, a decline of 92.08% compared to the same period last year[4]. - The net profit attributable to shareholders for the year-to-date period decreased by 54.15% to ¥1,808,364,213.46[3]. - Total operating revenue for the first three quarters of 2023 was CNY 4,968,894,713.90, a decrease from CNY 8,650,520,680.60 in the same period of 2022, representing a decline of approximately 42.5%[27]. - Net profit for the third quarter was CNY 1,811,765,538.11, down from CNY 4,039,308,595.96 in the same quarter of 2022, reflecting a decrease of approximately 55.2%[30]. - The total comprehensive income for the third quarter was CNY 1,811,765,538.11, down from CNY 4,039,308,595.96 in the same quarter of 2022, indicating a decrease of approximately 55.2%[30]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥891,075,081.56, a decrease of 71.37%[4]. - In the first three quarters of 2023, the cash inflow from operating activities was ¥5,282,460,049.00, a decrease from ¥7,045,784,158.72 in the same period of 2022, representing a decline of approximately 25%[31]. - The net cash flow from operating activities for the third quarter of 2023 was ¥891,075,081.56, significantly lower than ¥3,112,862,205.52 in the previous year[32]. - The total cash outflow from operating activities was ¥4,391,384,967.44 in the first three quarters of 2023, compared to ¥3,932,921,953.20 in the same period of 2022, indicating an increase of approximately 11.7%[33]. - The cash flow from operating activities was significantly impacted by a decrease in sales revenue, which fell to ¥5,060,001,699.65 from ¥6,832,443,576.77 in the previous year[31]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥16,464,312,266.40, an increase of 1.45% compared to the end of the previous year[4]. - The company's current assets totaled CNY 11,032,567,946.21, a decrease from CNY 12,179,759,105.13 in the previous year[19]. - The company's total liabilities were CNY 2,763,868,456.76 for current liabilities, down from CNY 3,485,189,792.38 in the previous year[25]. - Non-current liabilities totaled CNY 5,431,744,320.19, compared to CNY 4,049,757,465.99 at the end of 2022, indicating an increase[25]. - The total liabilities as of the end of the third quarter were CNY 2,969,653,761.50, compared to CNY 3,664,624,714.14 in the previous year, indicating a decrease of approximately 19%[28]. - The company's total equity reached CNY 13,494,658,504.90, an increase from CNY 12,564,891,856.98 year-over-year, representing a growth of about 7.4%[28]. Research and Development - The company capitalized research and development expenses related to the nasal spray COVID-19 vaccine in 2022, amounting to ¥4.22 billion, which was fully expensed in 2023[9]. - Research and development expenses for the first three quarters were CNY 812,675,493.88, compared to CNY 379,701,991.30 in the same period of 2022, reflecting an increase of approximately 114.3%[28]. - The company plans to continue its focus on R&D and market expansion despite the current financial challenges[6]. Inventory and Receivables - Accounts receivable stood at CNY 3,973,068,427.90, showing a slight increase from CNY 3,939,517,109.12 year-over-year[19]. - Inventory levels reached CNY 1,121,605,226.85, up from CNY 869,136,666.62, reflecting a significant increase in stock[19]. Investment Activities - The cash inflow from investment activities was ¥2,595,404,232.02 in the first three quarters of 2023, compared to ¥9,540,776,626.04 in the same period of 2022, indicating a decrease of about 72.8%[33]. - The net cash flow from investment activities was -¥1,507,474,676.07 for the first three quarters of 2023, an improvement from -¥2,880,828,622.70 in the same period of 2022[33]. - The cash outflow for investment activities was ¥4,102,878,908.09 in the first three quarters of 2023, compared to ¥3,834,906,248.74 in the same period of 2022, representing an increase of about 7%[33].
万泰生物:万泰生物关于召开2023年第三季度业绩说明会的公告
2023-10-25 08:49
证券代码:603392 证券简称:万泰生物 公告编号:2023-071 关于召开 2023 年第三季度业绩说明会的公告 北京万泰生物药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 会议召开时间:2023 年 11 月 3 日(星期五) 上午 11:00-12:00 会议召开地点: 上海证券 交 易 所 上 证 路 演 中 心 ( 网 址 : http://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 投资者可于 2023 年 10 月 27 日(星期五) 至 11 月 2 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wtzqb@ystwt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京万泰生物药业股份有限公司(以下简称"公司")计划于 2023 年 10 月 31 日发布公司 2023 年第三季度报告,为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况,公司计 ...
万泰生物:万泰生物关于以集中竞价交易方式首次回购公司股份的公告
2023-09-22 08:17
证券代码:603392 证券简称:万泰生物 公告编号:2023-069 北京万泰生物药业股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定,现将公司首次回购股份情况公告如下: 重要内容提示: 2023年9月22日,公司通过集中竞价交易方式首次回购公司股份100,000 股,已回购股份占公司总股本的比例为0.0079%,回购成交的最高价为48.79元/股、 最低价为48.06元/股,已支付的资金总额为人民币4,838,460.00元(不含交易佣金 等交易费用)。 一、回购股份的基本情况 公司于 2023 年 8 月 28 日召开第五届董事会第二十三次会议、第五届监事会 第二十三次会议,审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》,以上议案已经 2023 年 9 月 13 日召开的公司 2023 年第四次临时股东大会 审议通过,同意公司使用自有资金以集中竞价交易方式回购股份全部用于减 ...
万泰生物:万泰生物关于以集中竞价交易方式回购公司股份的回购报告书
2023-09-13 09:58
证券代码:603392 证券简称:万泰生物 公告编号:2023-067 北京万泰生物药业股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 回购股份的用途:全部用于减少公司注册资本。 回购价格:不超过98元/股(含),该回购价格上限不高于董事会审议通过本次回 购决议前30个交易日公司股票交易均价的150%。 回购资金来源:公司自有资金。 相关股东是否存在减持计划: 2、若公司在实施回购股份期间,受外部环境变化、临时经营需要等因素影响,致使 本次回购股份所需资金未能筹措到位,可能存在回购方案无法实施或者部分实施的风险; 3、本事项存在公司无法满足其他债权人清偿债务或提供担保进而导致回购方案难以 实施的风险; 4、因公司生产经营、财务状况、外部客观情况发生重大变化等原因,可能存在根据 规则变更或终止本次回购方案的风险; 5、如遇监管部门颁布新的回购相关规范性文件,导致本次回购实施过程中需要根据 回购资金总额:不低于人民币20,000万元(含)且不超过人民币4 ...
万泰生物:万泰生物关于回购股份通知债权人的公告
2023-09-13 09:58
证券代码:603392 证券简称:万泰生物 公告编号:2023-068 北京万泰生物药业股份有限公司 关于回购股份通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 2、债权人为自然人的,需同时携带有效身份证件的原件及复印件;委托他 人申报的,除上述文件外,还需携带授权委托书和代理人有效身份证件的原件及 复印件。 (二) 债权申报具体方式 北京万泰生物药业股份有限公司(以下简称"公司")于2023年8月28日召 开第五届董事会第二十三次会议、第五届监事会第二十三次会议,审议通过了《 关于以集中竞价交易方式回购公司股份方案的议案》。以上议案已经2023年9月 13日召开的公司2023年第四次临时股东大会审议通过。具体内容详见公司于2023 年8月29日、2023年9月14日在指定信息披露媒体披露的《北京万泰生物药业股份 有限公司关于以集中竞价交易方式回购公司股份方案的公告》(公告编号:2023- 062)、《北京万泰生物药业股份有限公司2023年第四次临时股东大会决议公告 》(公告编号:2023-066)。 根据公 ...
万泰生物:北京市中伦律师事务所关于北京万泰生物药业股份有限公司2023年第四次临时股东大会的法律意见书
2023-09-13 09:58
北京市中伦律师事务所 关于北京万泰生物药业股份有限公司 2023 年第四次临时股东大会的法律意见书 致:北京万泰生物药业股份有限公司 北京市中伦律师事务所(以下简称"本所")接受北京万泰生物药业股份有 限公司(以下简称"公司")的委托,就公司 2023 年第四次临时股东大会(以下 简称"本次会议")相关事宜,根据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司股东大会规则》《上海证券交易所股票上市规则》等法律、法 规和规范性文件及现行有效的《北京万泰生物药业股份有限公司章程》(以下简 称"公司章程"),依法出具本法律意见书。 本法律意见书仅就本次会议的召集和召开程序、出席会议人员资格、召集人 资格、本次会议表决程序及表决结果等事项发表法律意见,并不对本次大会所审 议议案的内容以及前述议案所表述的事实或数据的真实性和准确性发表意见。本 所律师并假定:公司提交给本所律师的所有资料(包括但不限于有关人员的居民 身份证、授权委托书、企业法人营业执照、证券账户卡、股东名册、网络投票结 果等)均真实、准确、完整;该等资料上的签字、印鉴均系真实,签署人均具有 完全的民事行为能力,且其签署行为已获得恰当、有效的授 ...
万泰生物:万泰生物2023年第四次临时股东大会决议公告
2023-09-13 09:58
证券代码:603392 证券简称:万泰生物 公告编号:2023-066 北京万泰生物药业股份有限公司 2023 年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: | 1、出席会议的股东和代理人人数 | | 63 | | --- | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 1,004,047,292 | | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 79.2162 | | | 份总数的比例(%) | | | (四)表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。 本次股东大会由公司董事会召集并发布公告通知,由公司董事长邱子欣先生 主持。会议表决方式为现场和网络投票相结合,本次大会的召集与召开程序、出 席会议人员资格及表决程序符合《公司法》及《公司章程》的规定。 重要内容提示: 本次会议是否有否决议案:无 一、 会议召开和出席情况 (一)股东大会召开的时间:2 ...
万泰生物:万泰生物关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
2023-09-07 08:24
证券代码:603392 证券简称:万泰生物 公告编号:2023-065 北京万泰生物药业股份有限公司 关于回购股份事项前十大股东和 前十大无限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 序号 股东名称 持股数量(股) 占公司总股本比例(%) 1 养生堂有限公司 705,807,928 55.65 2 钟睒睒 223,951,071 17.66 3 邱子欣 44,846,760 3.54 4 丁京林 15,894,057 1.25 5 邱明静 15,590,000 1.23 6 洪维岗 14,904,816 1.18 7 香港中央结算有限公司 14,283,575 1.13 8 李莎燕 9,703,563 0.77 9 李益民 7,585,938 0.60 一、前十大股东持股情况 | 10 | 中国银行股份有限公司-招商国证 6,878,372 0.54 | | --- | --- | | | 生物医药指数分级证券投资基金 | | 序号 | 股东名称 | 持股数量(股) | 占公司无限售条件 流通股 ...